Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
17 Nov 2023

Onconova Therapeutics (NASDAQ:ONTX) Third Quarter 2023 Results

Key Financial Results

  • Net loss: US$4.74m (loss narrowed by 12% from 3Q 2022).
  • US$0.23 loss per share (improved from US$0.26 loss in 3Q 2022).
NasdaqCM:ONTX Earnings and Revenue History November 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Onconova Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 1.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Onconova Therapeutics (2 shouldn't be ignored!) that you should be aware of.

What are the risks and opportunities for Onconova Therapeutics?

NasdaqCM:ONTX

Onconova Therapeutics

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.

View Full Analysis

Rewards

  • Revenue is forecast to grow 13.17% per year

Risks

  • Earnings are forecast to decline by an average of 27% per year for the next 3 years

  • Makes less than USD$1m in revenue ($226K)

  • Does not have a meaningful market cap ($13M)

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research onOnconova Therapeutics

ValuationFinancial HealthInsider TradingManagement Team

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10